BCAT1 and cancer: Innovative therapeutic strategies targeting BCAA pathways—ranging from selective small-molecule inhibitors (e.g., LAT1 and BCAT1/2) to dietary modulation—have shown promising preclinical and early clinical efficacy, highlighting their potential to exploit metabolic vulnerabilities in cancer cells while bolstering immune responses.